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Abstract
Class II MHC molecules display peptides on the cell surface for the surveillance by CD4+ T cells. To ensure that these ligands
accurately reflect the content of the intracellular MHC loading compartment, a complex processing pathway has evolved
that delivers only stable peptide/MHC complexes to the surface. As additional safeguard, MHC molecules quickly acquire a
‘non-receptive’ state once they have lost their ligand. Here we show now that amino acid side chains of short peptides can
bypass these safety mechanisms by triggering the reversible ligand-exchange. The catalytic activity of dipeptides such as
Tyr-Arg was stereo-specific and could be enhanced by modifications addressing the conserved H-bond network near the P1
pocket of the MHC molecule. It affected both antigen-loading and ligand-release and strictly correlated with reported
anchor preferences of P1, the specific target site for the catalytic side chain of the dipeptide. The effect was evident also in
CD4+ T cell assays, where the allele-selective influence of the dipeptides translated into increased sensitivities of the
antigen-specific immune response. Molecular dynamic calculations support the hypothesis that occupation of P1 prevents
the ‘closure’ of the empty peptide binding site into the non-receptive state. During antigen-processing and -presentation P1
may therefore function as important ‘‘sensor’’ for peptide-load. While it regulates maturation and trafficking of the complex,
on the cell surface, short protein fragments present in blood or lymph could utilize this mechanism to alter the ligand
composition on antigen presenting cells in a catalytic way.
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Introduction
The endosomal route is considered to be the default pathway for
the loading of class II MHC molecules. Here the MHC molecule
encounters internalized proteins serving as antigen source inside
the cell in an acidic lysosomal-like compartment (MIIC) [1,2].
However, experiments with fixed cells or MHC expressing cells
lacking key components of the processing pathway indicate that
MHC loading can take place also directly on the cell surface. This
applies not only for optimally sized peptides but also for larger
polypeptide chains or even full-length proteins [3–5]. In particular
immature dendritic cells (DC) could utilize this pathway. These
DC contain a large fraction of ‘empty’ class II MHC molecules on
the cell surface, which may allow the direct capturing of antigens
from the extracellular space [6,7].
While for these cells cell-surface processing seems to represent a
major antigen-loading pathway, on other cells it could cause
irregular immune responses. Namely on mature DC or activated B
cells the ligands presented on the cell surface should accurately
reflect the peptide composition inside the MIIC compartment.
Presumably as safeguard, a mechanism has evolved that prevents
the ‘accidental’ loading of class II MHC molecules. MHC
molecules, once they have lost their ligand, rapidly convert into
a stable inactive state that is ‘non-receptive’ for free peptides [8,9].
Neither the receptive nor the non-receptive conformation has been
structurally defined yet, so that they are characterized solely by
their kinetic parameters.
While in principle the conversion between the two forms is
reversible, the equilibrium is largely shifted towards the non-
receptive conformation. As a consequence, cell surface loading is
usually very inefficient, which hinders the induction of productive
immune responses during peptide vaccinations. In the endosomal
processing pathway MHC-loading is facilitated by HLA-DM, a
chaperone stabilizing the ‘peptide receptive’ state [10,11]. In
previous studies we have shown that surprisingly also small organic
compounds can exhibit this effect [12,13]. Similarly to HLA-DM,
these ‘MHC-loading enhancers’ (MLE) stabilize a peptide
receptive state resulting in accelerated antigen-loading and ligand
exchange. Here we demonstrate that not only simple organic
chemicals but also amino acid side chains can mediate this effect.
In experiments with short dipeptides we could demonstrate that
they can provoke both ligand exchange and peptide loading when
targeted to the conserved P1 anchor pocket of the class II MHC
molecule. The presence of ‘peptide-MLE’ during T cell assays
therefore significantly improved the cell surface loading of antigen
presenting cells (APC) with peptide antigens, which directly
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translated into an increased sensitivity of antigen-specific T cell
responses.
Results
Studies with synthetic organic MHC ligand-exchange catalysts
pointed already to the P1-pocket as specific target site for ‘MHC-
loading enhancer’ (MLE) [12]. The pocket is located in the
binding groove close to the N-terminal side of the peptide ligand.
In the ligand-complex the pocket accommodates the side chain of
a key anchor residue of the peptide (Fig. 1A). It was therefore
assumed that the MLE-effect may also be achieved with small
natural-like compounds consisting of amino acids. In order to test
this assumption soluble HLA-DR1 molecules were incubated with
the high-affinity peptide ligand HA306-318 in the presence of
amino acids or very short peptides. While free amino acids did not
exhibit any effect (data not shown) the simple dipeptide Tyr-Arg
(YR) accelerated the MHC-loading with the HA306-318 peptide
in a dose-dependent way (Fig. 1B). No effect was observed with the
Ala-Arg (AR) dipeptide lacking the aromatic anchor side chain,
indicating that the replacement of tyrosine by alanine completely
abrogated the MLE-effect.
As illustrated in Fig. 1A the stability of the MHC/ligand
complex is maintained by an H-bond network formed with the
backbone of the peptide. A considerable number of these bonds is
formed in the immediate vicinity of the P1-pocket. To further
stabilize the dipeptide by maximizing the number of H-bonds,
acetyl- and amide-groups were introduced to the N- and C-termini
of the dipeptides. Computational docking of acetylated dipeptide
amide Ac-YR-NH2 to the P1-pocket of HLA-DR1 indicates that
as much as five of the conserved H-bonds can be formed with this
minimal peptide (coordinates of the docking is enclosed in the
supplemental PDB-file PDB_Coordinates S1). Compared to the
free dipeptide YR a more than 10 fold increase in the catalytic
activity was observed with Ac-YR-NH2 (Fig. 2A). A partial MLE-
effect was observed also with Ac-YR and YR-NH2, whereas Ac-
AR-NH2 was still completely inactive. To confirm the importance
of a natural peptide structure, a dipeptide analogue to Ac-YR-
NH2 was employed in which tyrosine was replaced by b-
homotyrosine (b3hY). The introduction of this amino acid
increased the distance between the side chains by an additional
CH2-group and resulted in a total loss of activity (Fig. 2B).
Likewise any replacement of the standard L-amino acids by the
respective D-enantiomer abrogated the catalytic activity. Also the
dipeptide Ac-ry-NH2 composed of D-amino acids in inverse
sequence did not show any effect, indicating a strict stereo-
specificity of the catalyst (Fig. 2C).
Steric requirements, H-bond usage and in particular the failure
of dipeptides lacking the aromatic side chain further supported the
assumption that the effect was mediated by the dimorphic P1
pocket. The pocket of HLA-DR1 (DRB1*0101) contains the
residue b86G, which results in a preference for aromatic and, to a
lower extent, for aliphatic anchor residues [14]. To determine
whether these preferences are reflected in the catalytic activity of
peptide-MLE, a collection of acetylated dipeptide amides was
tested in which the tyrosine residue of Ac-YR-NH2 was replaced
by one of the two other aromatic amino acids phenylalanine (F)
and tryptophan (W) and by the aliphatic amino acids leucine (L),
methionine (M), isoleucine (I), and valine (V). In line with
expectation, strongest increase was observed with the dipeptides
containing F, Y or W, while the dipeptides with aliphatic side
chains showed weaker activity (Fig. 2D). No enhancement was
detected with Ac-ER-NH2 where tyrosine was substituted by
glutamate (E) which belongs to the residues not fitting in the P1
pocket of HLA-DR1 [15].
The mean catalytic MLE-activity is summarized in Table 1. For
soluble HLA-DR1 (DRB1*0101) the catalytic rate enhancement
coefficient was determined to be 6.5 mM21, 3.7 mM21 and
3.5 mM21, for minimal peptide-MLE containing F, Y and W
Figure 1. Amino acid side chains of short peptide fragments can catalyze the formation of MHC/ligand complexes. a) Location of P1
and the H-bond network in class II MHC molecules. Left panel: top view on the peptide binding site of the class II MHC molecule HLA-DR1. Only the
a1- (blue ribbon) and the b1-domain of the MHC molecule (red ribbon) are depicted; position of P1 is indicated. The backbone of the peptide ligand
HA306-318 and the anchor side chain filling the P1 pocket are shown in yellow; MHC residues forming H-bonds with the backbone are labelled in
grey. Right panel: side view of a P1 pocket loaded with the tyrosine anchor side chain. Surface of the pocket is indicated in yellow; amino acid
residues forming this pocket are indicated; the peptide is shown in spacefill mode (green). Images are based on the crystal structure of HA306-318/
HLA-DR1 (PDB: 1DLH) [38]. b) The catalytic impact of dipeptide side chains on the formation of antigen-complexes. The influence of short peptides on
the complex formation-rate between HA306-318 and soluble HLA-DR1 was determined. The loading reaction was carried out in the presence of
titrated amounts of the dipeptides Tyr-Arg (YR, filled circle) or Ala-Arg (AR, open circle) or in the absence of these dipeptides (dashed line). Complex
formation was determined by ELISA and is expressed as relative enhancement in reference to the spontaneous complex formation in the absence of
any catalyst. The amount of catalytic peptide fragments (MLE concentration) is indicated on the x-axis.
doi:10.1371/journal.pone.0001814.g001
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respectively. Compared to Ac-FR-NH2, the dipeptides with
aliphatic MLE side chains exhibited only between 12% (L) and
4% (V) of the activity. Similar catalytic activity was also detected
for some unmodified tripeptides as well as for two peptides derived
from invariant chain (LRMK, LRMKLPK) [16]. As ‘Ii-key’ they
had been described to facilitate MHC-loading by targeting an
allosteric invariant chain binding site located outside the P1
pocket. Their activity, however, was not significantly higher than
that of the unmodified tripeptides and the combined use with the
more active peptide-MLE Ac-FR-NH2 did not show any
cooperativity (data not shown). Notably, no effect was observed
for the N-terminal fragment of the invariant chain octapeptide
(LRKPPKPV). Although the fragment was reported to facilitate
antigen-loading and catalyze the self-release of the invariant chain
peptide IC106-120 (CLIP) [17] at least in this experimental system
no catalytic effect was observed.
So far, the impact of peptide-MLE was determined only on the
loading of empty MHC molecules. To evaluate their influence on
complex dissociation soluble class II MHC molecules were
preloaded with the medium affine CLIP peptide (Fig. 3). Although
the peptide binds to HLA-DR1 with lower affinity than HA306-
318 there was virtually no spontaneous decay detectable (left
Figure 2. Structure/activity relationships of catalytic dipeptides. a) Role of H-bonds for the catalytic activity of dipeptides. Various H-bond
bridges proximal to the P1 pocket stabilize the ligand complex (compare Fig. 1a). N-terminal acetylation and C-terminal amidation was introduced to
the YR dipeptide to facilitate the utilization of this H-bond network by minimal peptide-MLE catalysts. The influence was demonstrated in loading
reactions with HA306-318 and sol. HLA-DR1 in the presence of titrated amounts of YR (filled circle), Ac-YR (open circle), YR-NH2 (open triangle), Ac-YR-
NH2 (open square) and as control Ac-AR-NH2 (open diamond). b) Impact of elongated side chain spacing. A dipeptide derivative was used in which
the side chain spacing was elongated a single CH2-group by using the L-b-homotyrosine (Ac-b3hYR-NH2; open circle) instead of tyrosine (Ac-YR-NH2;
filled circle). c) Influence of D-amino acids. Complex formation was carried out in the presence of titrated amounts of Ac-YR-NH2 (filled circle), Ac-ry-
NH2 (open circle), Ac-rY-NH2 (open triangle), Ac-Ry-NH2 (open square), Ac-yR-NH2 (open diamond), Ac-Yr-NH2 (open triangle up), Ac-yr-NH2 (open
hexagon). D-amino acids are indicated by small letters. d) Structural requirements of the catalytic anchor side chain. The P1 pocket of HLA-DR1
interacts preferably with bulky hydrophobic anchor side chains. To compare the catalytic activity with the known structural preferences of P1 the
complex formation of HA306-318/HLA-DR1 is shown for Ac-FR-NH2 (filled circle), Ac-WR-NH2 (filled triangle down), Ac-YR-NH2 (filled square), Ac-LR-
NH2 (open circle), Ac-MR-NH2 (open triangle down), Ac-IR-NH2 (open square), Ac-VR-NH2 (open diamond), Ac-ER-NH2 (open triangle up).
doi:10.1371/journal.pone.0001814.g002
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panel). The same applies also when the experiment was carried out
in the presence of dipeptide-MLE. The situation looked different
when HA306-318 peptide was added (right panel). In less than
2 h, 50% of the HLA-DR1/CLIP complex disappeared when Ac-
FR-NH2 was present during dissociation. Notably, in the absence
of catalyst more than 80% of the complex still remained intact
even after 64 h of incubation indicating that the dipeptide-MLE is
able to increase also the off-rate of peptide-ligands. In the presence
of Ac-YR-NH2 and Ac-LR-NH2 the half-life was shortened to
,4 h and,10 h while Ac-AR-NH2 had only a very limited effect.
The reversible acceleration of both complex formation and
complex dissociation could therefore be correlated with the
anchor preference of the P1 pocket.
In order to formally demonstrate that the catalytic side chains of
peptide-MLE act through the P1 pocket, mutants of HLA-DR1 were
generated in which the glycine residue b86 at the floor of P1 was
replaced either by valine (b86V) or by tyrosine (ß86Y) (Fig. 4). In
HLA-DR, b86V represents the natural dimorphic alternate to
b86G. Occupation of b86 by valine produces a shallow hydrophobic
pocket that is able to accommodate aliphatic side chains but, in
contrast to b86G-pockets, is too small for bulky aromatic residues
[18]. The non-natural substitution b86Y has been shown to produce
MHC molecules that are highly receptive but contain a P1 pocket
blocked by the tyrosine residue [19]. Here, only those peptides can
bind where the binding does not depend on the P1 pocket.
Therefore, loading experiments were therefore carried out with
ABL908-922, a pentadecapeptide derived from the ABL kinase that
can form a complex with all three variants (Ho¨pner et al. manuscript
in preparation) (Fig. 4, upper panels). In the absence of any peptide-
MLE, ABL908-922 binds equally strong to wt HLA-DR1 (b86G)
and HLA-DR1 (b86GRV). Due to the inherently increased
receptiveness of the mutant [19], it exhibits the highest spontaneous
on-rate with HLA-DR1 (b86GRY). Also here the addition of
peptide-MLE resulted in increased loading reactions (Fig. 4, lower
panel). With wt HLA-DR1 (b86G) the enhancement of ABL908-922
loading corresponded to the result obtained with HA306-318, in
which the aromatic dipeptides showed stronger enhancements than
the aliphatic Ac-LR-NH2 peptide. The pattern was reversed for
HLA-DR1 (b86GRV). In line with the anchor preferences of the
shallow P1 pocket, best enhancement was obtained with Ac-LR-
Table 1. Catalytic activity of short peptides on the loading of
soluble HLA-DR1 with HA306-318
Compound*
Catalytic Rate Enhancement**
[6103 M-1 ]
rel. cat.
Activity*** [%]
a) Minimal peptide-MLE
1 Ac-FR-NH2 6.5 +/2 1.2 100
2 Ac-YR-NH2 3.7 +/2 1.0 57
3 Ac-WR-NH2 3.5 +/2 0.9 54
4 Ac-LR-NH2 0.76 +/2 0.08 12
5 Ac-MR-NH2 0.52 +/2 0.00 8
6 Ac-IR-NH2 0.43 +/2 0.01 7
7 Ac-VR-NH2 0.25 +/2 0.02 4
8 Ac-ER-NH2 0.02 +/2 0.02 0
9 Ac-AR-NH2 0.00 +/2 0.00 0
b) Catalytic tripeptides
10 YFR 0.68 +/2 0.29 11
11 YKT 0.59 +/2 0.12 9
12 KYV 0.51 +/2 0.15 8
13 GYV 0.49 +/2 0.16 8
c) ‘Invariant Chain’-derived peptides
14 LRMKLPK 0.98 +/2 0.21 15
15 LRMK 0.53 +/2 0.15 8
16 LRKPPKPV 0.00 +/2 0.00 0
*‘Minimal peptide-MLE’ and ‘catalytic tripeptides’ are introduced in this study,
catalytic activity for ‘invariant chain derived peptides’ has been reported for
LRMK and LRMKLPK [16] and for LRKPPKPV [17].
**The ‘Catalytic Rate Enhancement’ coefficient (k) represents the relative
increase of the spontaneous loading rate (rspont) in the presence of the
catalytic peptide (Pcat). The total rate (rtot) can be calculated by (rtot = rspont+
k [Pcat] rspont).
***‘‘rel. cat. Activity’’ indicates the relative catalytic activity of peptide derivatives
and is expressed as percentage in reference to the catalytic rate
enhancement of Ac-FR-NH2.
doi:10.1371/journal.pone.0001814.t001
Figure 3. Catalytic dipeptides trigger reversible ligand exchange. To demonstrate that peptide-MLE can catalyze the reversible ligand
exchange, complex dissociation of CLIP/HLA-DR1 induced by the peptide-MLE was determined in the absence (left panel) or presence of 200 mg/ml
free HA306-318 (right panel). In this experiment 10 mM Ac-FR-NH2, (filled circle), Ac-YR-NH2 (filled triangle), Ac-LR-NH2 (open circle), Ac-AR-NH2 (open
triangle) or no catalysts (cross) was used. The percentage of CLIP/HLA-DR1 complex remaining after indicated time points was determined by ELISA.
doi:10.1371/journal.pone.0001814.g003
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NH2 while weaker amplification was detected with aromatic
dipeptides. No enhancement was observed with HLA-DR1
(b86GRY). Even a slight reduction was detected at the highest
dipeptide concentration used, while 4-chlorophenol (pCP), a simple
disubstituted benzene known to act independent of P1 [12,13], still
exhibited an MLE-effect.
Exposure of cells to synthetic organic MLE facilitated the antigen
loading directly on cell surface MHC molecules [12,13]. To
determine whether this applies also for peptide-MLE, 721.221 cells
expressing HLA-DR1-GFP fusion proteins (721.221-DRb1GFP)
were incubated in the absence or presence of Ac-FR-NH2 with
biotinylated HA306-318 peptide. After staining with fluorescence-
labelled streptavidin, imaging of the cells by confocal laser scanning
microscopy revealed a striking increase in the amount of peptide
bound to the cell surface in the presence of Ac-FR-NH2 (Fig. 5A).
While almost no HA306-318 peptide was detectable when the
loading was carried out in the absence of the dipeptide-MLE, the
addition of the catalyst resulted in a bright surface staining that
colocalized with the HLA-DR1-GFP fusion protein.
In a more detailed analysis the peptide loading of cells was
analyzed by FACS (Fig. 5B). For these experiments fibroblast cells
were used that do not express endogenous class II MHC molecules
but were transfected with full length versions of wt HLA-DR1
(b86G) and mutated HLA-DR1 (b86GRV). As in the previous
experiment the cells were incubated with biotinylated MHC-
binding peptide ABL908-922 in the absence or presence of titrated
amounts of catalytic dipeptides (Fig. 5B, upper panels). Quanti-
fication of peptide-loading by FACS revealed a similar pattern as
observed before with soluble MHC molecules (compare Fig. 4).
On fibroblasts expressing wt HLA-DR1 the strongest enhance-
ment was observed with aromatic dipeptides, while the aliphatic
Ac-LR-NH2 peptide showed the weakest effect. Similar effects
were also observed with bone-marrow derived dendritic cells
obtained from HLA-DR1 transgenic mice (data not shown). On
cells expressing the mutated b86GRV molecule, the aliphatic Ac-
LR-NH2 was more effective than the peptide-MLE with aromatic
side chains. Thus, also the enhancement cell surface loading
correlated with the allele-specific anchor preferences of P1.
Importantly, the increased loading efficiency translated directly
into improved CD4+ T cell responses (Fig. 5B, lower panels).
CD4+ T cell hybridoma specific for the ABL epitope (SaABL/G2)
showed the strongest response when they were stimulated with
fibroblast cells that had been loaded before in the presence of the
dipeptides. The pattern of enhancement reflected the catalytic
Figure 4. Allele selectivity of catalytic dipeptides. Recombinant soluble HLA-DR1 molecules were mutated inside the P1 pocket and used in
loading experiments with ABL908-922, a peptide able to bind to wt as well as to the mutated forms of HLA-DR1 (S. Ho¨pner, unpublished). Upper
panels: the spontaneous loading of ABL908-922 is shown for wt HLA-DR1 (b86G), for HLA-DR1 (b86GRV) and HLA-DR1 (b86GRY). The formation of
ABL908-922/HLA-DR complex is expressed in counts per minute (cpm); dashed line indicates background signal. Lower panels: The allele-selective
effect of catalytic dipeptides is shown. The influence on HLA-DR loading is shown for Ac-FR-NH2 (filled circle), Ac-WR-NH2 (filled triangle down), Ac-
YR-NH2 (filled square) and Ac-LR-NH2 (open circle) and for p-chlorophenol (pCP; cross with dashed line), a simple aromatic MLE compound acting
independent of P1 [13]. 1.5 mg/ml ABL908-922 were used for wt HLA-DR1 and HLA-DR1 (b86GRV) and 0.2 mg/ml for HLA-DR1 (b86GRY). Complex
formation is expressed as relative enhancement in reference to the spontaneous complex formation in the absence of any catalyst. The loading was
determined by ELISA.
doi:10.1371/journal.pone.0001814.g004
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effect on antigen loading as it directly correlated with the allele-
specific P1-anchor preference. Aromatic dipeptides were most
efficient on wt HLA-DR1 (b86G) while the aliphatic Ac-LR-NH2
showed best stimulation with cells expressing the mutated HLA-
DR1 (b86GRV) with the shallow P1 pocket.
The influence of catalytic dipeptides on the CD4+ T cell
response was further studied in in vitro T cell assays in which T cells
and APC were exposed to free peptide antigens and peptide-MLE.
In these experiments HA306-318 was used as antigen to challenge
two different HLA-DR-restricted CD4+ T cells, the mouse T cell
hybridoma EvHA/X5 (Fig. 6A, upper panels) and the human T
cell line PD2 (Fig. 6A, lower panels). For both cell lines the
presence of peptide-MLE resulted in a drastic increase in the
sensitivity of the T cell response. Titration of the peptide-MLE at
suboptimal antigen dosage revealed maximal enhancement of the
T cell response at concentrations around 2–3 mM (left panels). At
these concentrations the dose response curves for the HA306-318
antigen were shifted up to 50-fold towards lower concentrations
(right panels). While a half-maximal response in the absence of
catalyst was detected at a concentration of 31 ng/ml for EvHA/
X5 and of 14 ng/ml for PD2, Ac-FR-NH2 lowered the threshold
to 0.65 ng/ml and 0.23 ng/ml, respectively. In line with the
previous data weaker effects were determined with Ac-LR-NH2.
Lastly, to confirm that peptide-MLE mediated enhancement
can be observed also with primary cells, lymph node cells from
HLA-DR1tg mice were challenged ex vivo in the absence or
presence of Ac-FR-NH2. The mice were primed either with
HA306-318 or with NY-ESO-1 89-101, a CD4+ T cell epitope
derived from the NY-ESO-1 protein associated with various solid
tumours [20]. After 12 days the antigen-specific ex vivo response
was determined by an IFN-c ELISPOT assay (Fig. 6B). In line
with the previous results, the catalytic dipeptide was found to
significantly increase the sensitivity of the assay. At concentrations
of 5 ng/ml HA306-318 (upper panel) and of 50 ng/ml NY-ESO-1
89-101 (lower panel) the number of spots representing single IFN-c
secreting cells was significantly higher when the Ac-FR-NH2 was
added. Thus, short peptides exhibiting MLE-like activity can
amplify immune responses also in primary cultures containing
‘natural’ CD4+ T cells and professional APC.
Discussion
Our experimental data show that short peptide fragments can
influence the ligand composition of class II MHC molecules in a
catalytic way. By placing an amino acid side chain into a defined
pocket of the MHC molecule they trigger ligand-exchange and
antigen-loading. Mutational analysis indicated already that the
occupation of pocket P1 is crucial for the catalytic effect of organic
MLE compounds [12]. As demonstrated here for the human
molecule HLA-DR1, a similar role could also be established for the
ligand exchange driven by short peptides. P1 is present in all MHC
class II molecules. It is located within the peptide binding site and
accommodates the side chain of a key-anchor residue of the peptide
ligand. While the location of the pocket is conserved, it contains
polymorphic residues that determine allele-specific preferences for
anchor residues. Since the same structural requirements also dictate
the interaction with ‘catalytic’ side chains of short peptides, they
exhibit their effect in an allele-selective way.
As shown before for simple organic compounds the MLE
mechanism is based on the stabilization of the peptide-receptive
Figure 5. Enhanced loading of cell surface MHC by peptide-MLE. a) Confocal laser scanning analysis of cell surface loading. 721.221-DRb1GFP
cells expressing a GFP-tagged HLA-DR1 molecule were incubated with biotinylated HA306-318 peptide in the absence or presence of Ac-FR-NH2.
After staining with streptavidin-Cy5 images were taken by confocal laser scanning microscopy. Scale bar represents 10 mm. b) Impact on APC loading
and T cell response. Fibroblast transfectants expressing either wt HLA-DR1 (left panels) or mutated HLA-DR1 (b86GRV; right panels) were incubated
with ABL908-922 in the presence of titrated amounts of Ac-FR-NH2 (filled circle), Ac-WR-NH2 (filled triangle), Ac-YR-NH2 (filled square), Ac-LR-NH2
(open circle) or in the absence of any peptide-MLE. Upper panels: Analysis of cell surface loading by FACS. Fibroblast cells were incubated with 12 mg/
ml biotinylated ABL908-922. After 4h peptide loading was determined by FACS and is expressed as geometrical mean (geo. mean). Lower panels:
Enhancement of the ABL908-922-specific T cell response. Fibroblast cells expressing wt HLA-DR1 or HLA-DR1 (b86GRV) were incubated for 4 h with
150 ng/ml or 300 ng/ml ABL908-922, washed and used to challenge SaABL1/G2, an ABL908-922 specific T cell hybridoma that recognizes the peptide
on both HLA-DR1 molecules. The response is expressed as IL-2 release; dashed lines represent the T cell response triggered in the absence of any MLE
compounds.
doi:10.1371/journal.pone.0001814.g005
Ligand-Exchange Catalysts
PLoS ONE | www.plosone.org 6 2008 | Volume 3 | Issue 3 | e1814
conformation [12]. Earlier studies showed already that the
substitution of residue b86G by tyrosine resulted in a ‘filled’ P1
pocket and produced an MHC molecule with elevated receptive-
ness [21]. P1 is located proximal to the binding site of HLA-DM
and binding studies suggested that HLA-DM interacts specifically
with the flexible empty hydrophobic P1-pocket [21]. While the
active conversion of a non-receptive molecule by HLA-DM has
recently been questioned [22], it is undisputed that the chaperone
interacts with a region proximal to P1 to stabilize the peptide
receptive conformation [10,11,23,24].
In a recent publication we introduced a model in which the
transition to the non-receptive state is directly correlated with
structural changes inside pocket P1. Experimental evidence was
taken from the observation that P1-targeting MLE compounds
prevent this transition [12]. The strict correlation of the catalytic
activity with the structural requirements of P1 introduced by this
study provides additional support to the hypothesis that the
stabilization of P1 prevents the transition into the non-receptive
state. A molecular dynamic (MD) simulation confirmed that the
pocket P1 is indeed quickly lost when the peptide ligand is stripped
off from the MHC molecule (Rupp et al. manuscript in
preparation) (Fig. 7). Calculations based on the coordinates of
the crystal structure of the HLA-DR1/HA306-318 complex
revealed that the most significant transitions were detected near
the P1 pocket. While these shifts resulted in a narrowing of the two
a-helices by more than 7A˚ (Fig. 7A), they also led to a complete
loss of the P1 pocket. In less than 15 ns the P1 cavity was filled
with side chains or removed by distortions (Fig. 7C,D). Notably,
this collapse was prevented when prior to the MD simulation the
Ac-FR-NH2 was docked into the P1 pocket (Fig. 7B).
Based on this model even the partial occupation of the binding site
by a very short peptide is sufficient to stabilize the receptive state as
long as it positions an anchor side chain inside the P1-pocket
(supplemental PDB file PDB_Coordinates S1). P1 therefore seems to
function as a sensor for the peptide load where occupation leads to a
stabilization of the ‘open’ conformation required to accommodate
the peptide ligand. Studies by other groups have already shown that
the loading status of P1 plays a crucial role as indicator in the
intracellular antigen-processing pathway. The interaction with
HLA-DM seems to depend on the loading state [21] and its catalytic
activity was reported to be mediated by bH81, a conserved residue
located on top of the P1 pocket [24].
While inside the cell the occupational state of P1 seems to
control the interaction with key-components of the processing
pathway, on the cell surface it may regulate the transition into the
non-receptive conformation. Here, it functions as trigger for a
safeguard mechanism that closes the binding site as soon as the
ligand is lost. In this study we showed that small peptide fragments
can by-pass this mechanism in a catalytic way. Particularly striking
is the effect on the ligand exchange. Peptide-MLE were able to
increase not only the loading of empty HLA-DR molecules but
also the dissociation of HLA-DR molecules preloaded with lower-
Figure 6. Amplification of the antigen-specific T cell response. a) Enhancement of the in vitro T cell response. The influence of catalytic peptides
on the antigen-specific CD4+ T cell response was tested with a mouse T cell hybridoma EvHA/X5 (upper panels) and a human T cell line PD2 (lower
panels). Both recognize the HA306-318 antigen in the context of HLA-DR1. The left panels show the influence of titrated amounts of Ac-FR-NH2 (filled
circle), Ac-YR-NH2 (filled triangle) or Ac-LR-NH2 (open circle) by EvHA/X5 and PD2 in the presence of 15 or 2 ng/ml HA306-318, respectively. The response
in the absence any catalyst is indicated as a dashed line. The right panels are showing the dose response curves of HA306-318 in the presence of 5 mMAc-
FR-NH2 (filled circle) or Ac-LR-NH2 (open circle), 3 mM Ac-YR-NH2 (filled triangle) or in the absence of any peptide-MLE (cross). Dashed line indicates the
background. b) Enhancement of the ex vivo T cell response. Lymph node cells were isolated fromHLA-DR1tg mice primed with HA306-318 peptide or NY-
ESO-1 89-101. The ex vivo response was determined by an IFN-c ELISPOT assay by challenging the cells with 5 ng/ml HA306-318 (upper panel) or 50 ng/ml
NY-ESO-1 89-101 (lower panel), respectively. The bars represent the number of spots detected in the absence (black bar) or presence of 2.5 mMAc-FR-NH2
(grey bar). Each spot originates from a single IFN-c secreting cell; dashed line indicates the background signal.
doi:10.1371/journal.pone.0001814.g006
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affinity ligands in a reversible reaction. Both effects should account
for the increased antigen-loading of cell surface MHC molecules,
which translated directly into improved CD4+ T cell responses. As
molecular tool MLE compounds may therefore find applications in
experimental and therapeutic settings in which improved antigen
loading is desired. A particular suitable field may be peptide-based
tumour immune interventions, where the exposure of antigen to a
hostile proteolytic environment is extended by the limited access to
receptive MHC molecules on the surface of professional APC.
While the importance of CD4+ T cells for productive tumour
immune responses has just begun to be fully discovered [25] their
role in the induction of autoimmune responses has long been
acknowledged [26]. It is evident for instance in the strong genetic
link to class II MHC molecules and in the fact that experimental
autoimmune diseases can often be induced by the adoptive
transfer of auto-aggressive CD4+ T cells. In this respect
‘accidental’ loading of these cells with self-antigens by peptide-
MLE may therefore trigger unwanted auto-aggressive responses.
In vitro we have shown already that the presence of simple organic
MLE compounds can enhance encephalitogenic T cell responses
[12,13]. The same may also apply for colitis or celiac disease.
Intestinal dendritic cells are known to penetrate gut epithelia cells
[27] and expose their dendrites inside the gut lumen to extremely
high polypeptide concentrations originating from the diet or
commensal debris. Capture of soluble antigens by immature DC
from lymph or blood, on the other hand, also seems to be an
important mechanism for tolerance induction [28] and direct cell
surface loading has been discussed as an alternative processing
pathway of immature dendritic cells [6,7]. Natural protein
fragments present in blood or lymph acting as peptide-MLE
may therefore participate in this process by mediating the direct
transfer of antigens onto cell surface MHC molecules.
Materials and Methods
Compounds and reagents
The following peptides were used: IC106-120 (KMRMATPL-
LMQALPM; ‘CLIP’ peptide) [29], HA306-318 (PKYVKQNT-
LKLAT) [30], NY-ESO-1 89-101 (EFYLAMPFATPME) [20] and
human ABL 908-922 (KGKLSRLKPAPPPPP) (Hopner et al.,
Figure 7. Molecular dynamic (MD) calculation of ‘empty’ and peptide-MLE stabilized HLA-DR1. The coordinates of the MHC component
of the crystallized HLA-DR1/HA306-318 complex (1DHL) were used to carry out a 15 ns MD calculation with an ‘empty’ MHC molecule. a) Dynamic of
the empty MHC molecule. The floor composed of the b-plated sheats is depicted in magenta, the a-helices of the starting structure are shown in red,
a-helices of the structure obtained after 15 ns are shown in blue. The approximate position of P1 is indicated. While the dynamic was carried out with
all extracellular domains, only the binding site is shown (a1-, b1-domain). b) Dynamic of the peptide-MLE stabilized MHC molecule. The same MD
calculation was carried out as in Fig. 7a except that coordinates of an HLA-DR1 molecule were used, in which prior to the MD calculation the peptide-
MLE Ac-FR-NH2 was docked into the P1 pocket. c) P1 pocket in the peptide loaded MHC complex. The image shows a cross-section of the HLA-DR1/
HA306-318 complex. The surface of the MHC molecule is shown in yellow, the peptide ligand in red; position of the P1 pocket is indicated. d) Loss of
P1 in the empty MHC molecule. The same cross-section shown in Fig. 7c for the peptide-loaded MHC is shown here for the empty molecule obtained
after 15 ns of MD calculation. In this structure the P1 pocket can no longer be located.
doi:10.1371/journal.pone.0001814.g007
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unpublished). N-terminal biotinylation was introduced using two
6-amino hexanoic acid spacer units. Stock solutions of short
peptides (100 mM) were prepared with DMSO/PBS after
ultrasound sonication at the following DMSO concentrations:
YR, AR (0%); LRMK, YFR, GYV, Ac-AR-NH2, Ac-ry-NH2, Ac-
rY-NH2, Ac-Ry-NH2, Ac-yR-NH2, Ac-Yr-NH2 and Ac-b3hYR-
NH2 (10%); Ac-FR-NH2, Ac-YR-NH2, Ac-LR-NH2, Ac-ER-NH2
(15%); LPKPPKPV (20%); Ac-WR-NH2 (25%); Ac-VR-NH2, Ac-
MR-NH2, Ac-IR-NH2, Ac-RY-NH2 (100%). All peptides were
produced by EMC microcollections GmbH (Tu¨bingen, Germany)
and analyzed by RP-HPLC (214 nm) and ESI-MS.
Antibodies and soluble HLA-DR1
Phycoerythrin- (PE) conjugated streptavidin was purchased from
Caltag, a-HLA-DR-PE (L243) was obtained from BD Biosciences.
Unlabelled a-HLA-DR (L243) and a-IFN-c (AN18.1724 and R4-
6A2) were purified from hybridoma supernatant by Prot.A and
Prot.G columns (GE Healthcare). R4-6A2 was labeled with NHS-
Biotin according to the manufactures recommendation (Pierce).
Soluble wt HLA-DR1 (DRA*0101, DRB1*0101) [31] was produced
in S2 insect cells as described [13]. Mutant forms of HLA-DR1 were
expressed in a baculovirus expression system. Briefly, DNA coding
for the extracellular domains of DRA*0101 and DR1B*0101 was
separately cloned into the transfer vector pFastbac 1 (Invitrogen).
Leucine zipper domains were added to the C-termini of the a- and b-
chain as described [32]. Site-directed mutagenesis of HLA-DR1 b-
chain was carried out using the QuickChange site-directed
mutagenesis kit (Stratagene). Recombinant viruses were generated
in S. frugiperda cells (Sf21). For expression of proteins, cells were co-
infected with viruses for the a- and b-chain.
Cells
The following class II expressing cell lines were used: L929
fibroblasts (ATCC) transfected with wt (DRB1*0101) or mutated
HLA-DR1 (HLA-DRB1*0101 b86V) [12], EBV-transformed B
cell 721.221 (ATCC) and HTR [33]. 721.221-DRb1GFP cells
were produced by stably transfecting 721.221 cells with a HLA-
DR ß-chain (DRB1*0101) C-terminally fused to EGFP (Falk et al.
unpublished). The following T cells were used: DRB1*0101-
restricted, HA306-318-specific mouse hybridoma line EvHA/X5
[12] and human CD4+ T cell line PD2 [33]; the ABL 908-922-
specific T cell hybridoma SaABL/G2 was generated after fusing a
CD4+ T cell line generated in HLA-DR1 tg mice [34] with BW
cells (Hopner et al., unpublished).
Peptide loading of soluble HLA-DR1 molecules
Loading experiments with soluble MHC molecules were carried
out as described [13]. Briefly, 100 nM HLA-DR1 was incubated
with 50 mg/ml of biotinylated HA306-318 peptide (PBS, pH 7.4,
37uC, 1 h). The amount of peptide/MHC complex formed was
determined by ELISA with the a-HLA-DR capture antibody (L243,
ATCC) and Eu3+-labelled streptavidin (DELFIA,Wallac) using a
Victor 3V reader (Perkin Elmer). Ligand exchange experiments were
carried out with preloaded HLA-DR1/CLIP complexes (1,5 mM
HLA-DR1, 50 mg/ml biotinylated CLIP, 18-20 h, pH 7.4, 5%
ethanol/PBS) diluted 1:15 and incubated with or without 200 mg/ml
HA peptide in presence and absence of 10 mM dipeptide [12]. All
experiments are carried out at 2 or 3 times.
Peptide loading of cell surface MHC molecules
Loading experiments were carried out as described [12]. Briefly,
16105 HLA-DR expressing cells/well were incubated with
biotinylated MHC-binding peptides in presence and absence of
catalytic dipeptides (4 h, 37uC, DMEM, 5% FCS, 96 well V-
bottom plates). For FACS analysis cells were stained with
streptavidin-PE and analyzed on a FACScalibur instrument (BD
Biosciences). Dead cells were excluded by propidium iodide
staining. Experiments were carried out twice.
Confocal laser scanning microscopy
Briefly, 16105 HLA-DR1 expressing cells (721.221-DRb1GFP)
per well were incubated with 20 mg/ml of biotinylated HA 306-
318 peptide in presence and absence of 2.5 mM Ac-FR-NH2 (4 h,
37uC, DMEM, 5% FCS, 96 well V-bottom plates). Cells were then
washed and were incubated on poly-L-lysine (sigma) coated plates
for 30 min. at 37uC in RPMI medium (Gibco), followed by a
15 min. 3.7% formaldehyde fixation. After washing cells were
stained with streptavidin-Cy5 (Amersham) and mounted with
vectashield (vector labs). Fixed cell microscopy was performed with
a Zeiss LSM510Meta confocal setup (636 phase contrast plan-
apochromat oil objective). Experiments were carried out twice.
T cell assays
T cell assays were carried out as described [13]. Briefly, 56104
HLA-DR expressing cells/well were incubated with MHC-binding
peptides in presence and absence of catalytic dipeptides (37uC,
DMEM, 5% FCS, 96 well round-bottom plates). In assays with
antigen-pulsed APC, cells were washed after 4 h before 56104 T
cells were added, in permanent exposure assays the T cells were
added directly without prior removal of the peptides. In experiments
with T cell hybridoma the culture supernatant was removed after
24 h and the T cell response was determined by measuring IL-2
release in a secondary assay with CTLL cells (ATCC) as described
previously [35]. In experiments with T cell lines, APC were radiated
with 60.7 Gy and 3H-thymidine was added after 48h and the
incorporation was determined using a 1450 Microbeta counter
(Wallac). Experiments were carried out twice.
Detection of ex vivo response by ELISPOT assay
HLA-DR1tg mice were primed with 5 mg HA306-318 or 10 mg
NY-ESO-1 89-101 in incomplete Freud’s adjuvant (Sigma)/50 mg
CpG OND 1826 (BioTez GmbH). On day 12, lymph node cells
were isolated and incubated in ELISPOT-plates (Multiscreen HTS
96 well Filteration plate; Millipore) coated with a-IFN-c (clone
AN18.1724). Cells were incubated at a density of 16106
splenocytes/well with indicated amounts of HA306-318 and Ac-
FR-NH2 peptide (20–40 h, 37uC, 5% CO2, RPMI 5% FCS).
Detection was carried out according to manufacturer’s recommen-
dation using the biotinylated a-IFN-c detection antibody (clone R4-
6A2), avidin–HRP enzyme conjugate (Sigma) and 3,3 diaminoben-
zidine tablets (Sigma). Spots were counted using ‘Immunospot’
reader (C.T.L Europe GmbH). Experiments were carried out twice.
Calculation of the ‘catalytic rate enhancement’
The ‘catalytic rate enhancement’ coefficient was determined in
loading assays with 100 nM soluble HLA-DR1 and 50 mg/ml
HA306-318 with titrated amounts of the catalytic peptide-MLE (1 h,
37uC, pH 7.4). A curve fit was carried out by a hyperbola regression
(f(x) = ax/(b+x)) using the Sigmaplot Version 9.0 software (Systat
Software Inc.) and the coefficient was determined by forming the
average of the starting slope (a/b) of 2–4 independent experiments.
Docking and ‘Molecular Dynamics’ calculation
The benzene ring of the phenylalanine residue and the
backbone of the Ac-FR-NH2 dipeptide were superimposed to
the residues Y308 and V309 of the HA306-318 peptide in the
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HA306-318/HLA-DR1 crystal structure 1DLH, followed by a
conformation search with the arginine side chain of the dipeptide
to find an optimal orientation. Subsequently, the complex
structure was minimized using the Tripos software (SYBYL 7.3,
Tripos Inc., St. Louis, USA) and the GROMACS force field [36].
For both, the empty MHC structure and the Ac-FR-NH2/MHC-
complex, a 15 ns molecular dynamic simulation in the GRO-
MACS force field was performed (Rupp et al., manuscript in
preparation). The simulations were done under physiological
conditions (0.9% NaCl, 310 K) after equilibration over a period of
500 ps using a positional restraint of 1000 kJmol21nm22. Frames
were stored every 5 ps, visualisation of trajectories and arrange-
ment of the figures were realised using VMD [37].
Supporting Information
PDB_Coordinates S1 The text file contains the calculated
coordinates of the complex Ac-FR-NH2/HLA-DR1 in PDB-file
format. For the docking of Ac-FR-NH2 the benzene ring of the
phenylalanine residue and the backbone of the dipeptide were
superimposed to the residue Y308 (located within the P1 pocket)
and V309 of the HA306-318 peptide in the HA-306-318/HLA-
DR1 crystal structure 1DLH. Subsequently, the complex was
minimized using Tripos and the GROMACS force field. Chain A:
HLA-DR1 a-chain (DRA*0101); chain B: HLA-DR1 b-chain
(DRB1*0101); chain C: Ac-FR-NH2
Found at: doi:10.1371/journal.pone.0001814.s001 (0.26 MB
TXT)
Acknowledgments
We thank S. Kleißle for technical assistance and S. Giering for help in
preparing the manuscript.
Author Contributions
Conceived and designed the experiments: OR SG SH RK GJ KF.
Performed the experiments: SG SH SG KD NA BR. Analyzed the data:
OR KW SG SH SG KD NA RK GJ KF BR. Contributed reagents/
materials/analysis tools: MC KW GJ BR. Wrote the paper: OR KF.
References
1. Stern LJ, Potolicchio I, Santambrogio L (2006) MHC class II compartment
subtypes: structure and function. Curr Opin Immunol 18: 64–69.
2. Watts C (2001) Antigen processing in the endocytic compartment. Curr Opin
Immunol 13: 26–31.
3. Pinet V, Vergelli M, Martin R, Bakke O, Long EO (1995) Antigen presentation
mediated by recycling of surface HLA-DR molecules. Nature 375: 603–606.
4. Vergelli M, Pinet V, Vogt AB, Kalbus M, Malnati M, et al. (1997) HLA-DR-
restricted presentation of purified myelin basic protein is independent of
intracellular processing. Eur J Immunol 27: 941–951.
5. Marin-Esteban V, Falk K, Rotzschke O (2003) Small-molecular compounds
enhance the loading of APC with encephalitogenic MBP protein. J Autoimmun
20: 63–69.
6. Santambrogio L, Sato AK, Carven GJ, Belyanskaya SL, Strominger JL, et al.
(1999) Extracellular antigen processing and presentation by immature dendritic
cells. Proc Natl Acad Sci U S A 96: 15056–15061.
7. Santambrogio L, Sato AK, Fischer FR, Dorf ME, Stern LJ (1999) Abundant
empty class II MHC molecules on the surface of immature dendritic cells. Proc
Natl Acad Sci U S A 96: 15050–15055.
8. Natarajan SK, Assadi M, Sadegh-Nasseri S (1999) Stable peptide binding to
MHC class II molecule is rapid and is determined by a receptive conformation
shaped by prior association with low affinity peptides. J Immunol 162:
4030–4036.
9. Rabinowitz JD, Vrljic M, Kasson PM, Liang MN, Busch R, et al. (1998)
Formation of a highly peptide-receptive state of class II MHC. Immunity 9:
699–709.
10. Denzin LK, Hammond C, Cresswell P (1996) HLA-DM interactions with
intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing
empty HLA-DR molecules. J Exp Med 184: 2153–2165.
11. Kropshofer H, Arndt SO, Moldenhauer G, Hammerling GJ, Vogt AB (1997)
HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules
at lysosomal pH. Immunity 6: 293–302.
12. Hopner S, Dickhaut K, Hofstatter M, Kramer H, Ruckerl D, et al. (2006) Small
organic compounds enhance antigen loading of class II major histocompatibility
complex proteins by targeting the polymorphic P1 pocket. J Biol Chem 281:
38535–38542.
13. Marin-Esteban V, Falk K, Rotzschke O (2004) ‘‘Chemical analogues’’ of HLA-
DM can induce a peptide-receptive state in HLA-DR molecules. J Biol Chem
279: 50684–50690.
14. Rammensee H-G, Bachmann J, Stevanovic S (1997) MHC Ligands and Peptide
Motifs. Austin, TX: Springer Verl; Landis Biosciences.
15. Fleckenstein B, Kalbacher H, Muller CP, Stoll D, Halder T, et al. (1996) New
ligands binding to the human leukocyte antigen class II molecule DRB1*0101
based on the activity pattern of an undecapeptide library. Eur J Biochem 240:
71–77.
16. Xu M, Li J, Gulfo JV, Von Hofe E, Humphreys RE (2001) MHC class II
allosteric site drugs: new immunotherapeutics for malignant, infectious and
autoimmune diseases. Scand J Immunol 54: 39–44.
17. Kropshofer H, Vogt AB, Stern LJ, Hammerling GJ (1995) Self-release of CLIP
in peptide loading of HLA-DR molecules. Science 270: 1357–1359.
18. Ong B, Willcox N, Wordsworth P, Beeson D, Vincent A, et al. (1991) Critical
role for the Val/Gly86 HLA-DR beta dimorphism in autoantigen presentation
to human T cells. Proc Natl Acad Sci U S A 88: 7343–7347.
19. Natarajan SK, Stern LJ, Sadegh-Nasseri S (1999) Sodium dodecyl sulfate
stability of HLA-DR1 complexes correlates with burial of hydrophobic residues
in pocket 1. J Immunol 162: 3463–3470.
20. Chen Q, Jackson H, Parente P, Luke T, Rizkalla M, et al. (2004)
Immunodominant CD4+ responses identified in a patient vaccinated with full-
length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad
Sci U S A 101: 9363–9368.
21. Chou CL, Sadegh-Nasseri S (2000) HLA-DM recognizes the flexible
conformation of major histocompatibility complex class II. J Exp Med 192:
1697–1706.
22. Grotenbreg GM, Nicholson MJ, Fowler KD, Wilbuer K, Octavio L, et al. (2007)
Empty Class II Major Histocompatibility Complex Created by Peptide
Photolysis Establishes the Role of DM in Peptide Association. J Biol Chem
282: 21425–21436.
23. Doebele RC, Busch R, Scott HM, Pashine A, Mellins ED (2000) Determination
of the HLA-DM interaction site on HLA-DR molecules. Immunity 13: 517–527.
24. Narayan K, Chou CL, Kim A, Hartman IZ, Dalai S, et al. (2007) HLA-DM
targets the hydrogen bond between the histidine at position beta81 and peptide
to dissociate HLA-DR-peptide complexes. Nat Immunol 8: 92–100.
25. Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, et al. (2005) Primary
antitumor immune response mediated by CD4+ T cells. Immunity 22: 371–383.
26. Jones EY, Fugger L, Strominger JL, Siebold C (2006) MHC class II proteins and
disease: a structural perspective. Nat Rev Immunol 6: 271–282.
27. Rescigno M, Urbano M, Valzasina B, Francolini M, Rotta G, et al. (2001)
Dendritic cells express tight junction proteins and penetrate gut epithelial
monolayers to sample bacteria. Nat Immunol 2: 361–367.
28. Hochweller K, Sweenie CH, Anderton SM (2006) Immunological tolerance
using synthetic peptides–basic mechanisms and clinical application. Curr Mol
Med 6: 631–643.
29. Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P (1992) HLA-
DR molecules from an antigen-processing mutant cell line are associated with
invariant chain peptides. Nature 360: 474–477.
30. Lamb JR, Eckels DD, Lake P, Woody JN, Green N (1982) Human T-cell clones
recognize chemically synthesized peptides of influenza haemagglutinin. Nature
300: 66–69.
31. Sloan VS, Cameron P, Porter G, Gammon M, Amaya M, et al. (1995)
Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 375:
802–806.
32. Fourneau JM, Cohen H, van Endert PM (2004) A chaperone-assisted high yield
system for the production of HLA-DR4 tetramers in insect cells. J Immunol
Methods 285: 253–264.
33. Falk K, Rotzschke O, Strominger JL (2000) Antigen-specific elimination of T
cells induced by oligomerized hemagglutinin (HA) 306-318. Eur J Immunol 30:
3012–3020.
34. Rosloniec EF, Brand DD, Myers LK, Whittington KB, Gumanovskaya M, et al.
(1997) An HLA-DR1 transgene confers susceptibility to collagen-induced
arthritis elicited with human type II collagen. J Exp Med 185: 1113–1122.
35. Falk K, Lau JM, Santambrogio L, Esteban VM, Puentes F, et al. (2002) Ligand
exchange of major histocompatibility complex class II proteins is triggered by H-
bond donor groups of small molecules. J Biol Chem 277: 2709–2715.
36. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, et al. (2005)
GROMACS: fast, flexible, and free. J Comput Chem 26: 1701–1718.
37. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics.
J Mol Graph 14: 33–3827–38.
38. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, et al. (1994) Crystal
structure of the human class II MHC protein HLA-DR1 complexed with an
influenza virus peptide. Nature 368: 215–221.
Ligand-Exchange Catalysts
PLoS ONE | www.plosone.org 10 2008 | Volume 3 | Issue 3 | e1814
